Has Humanizing the Drug Discovery and Development Process with Organ-On-Chips Contributed to Breaking Eroom’s Law?

Basit Öğe Kaydı
dc.contributor.authorYesil-Celiktas O.
dc.contributor.authorFiliz Y.
dc.date.accessioned2024-08-31T07:42:14Z
dc.date.available2024-08-31T07:42:14Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description2023 International Conference on Research in Education and Science, ICRES 2023 -- 18 May 2023 through 21 May 2023 -- Cappadocia -- 196574en_US
dc.description.abstractThe drug discovery and development process is time and cost intensive. Eroom’s law published with data up to 2010, stated that total costs of research and development (R&D) on new drugs approved by the US Food and Drug Administration had risen exponentially for 60 years. However, the changes in the costs associated with failed new molecular entities have started to decline, which led to the breaking of the rule. In this study, organ-on-chips are hypothesized as another valid reason, breaking Eroom’s Law as key parameters related to molecular, cellular and physiological features of human disease progression have been considered while developing such models. Although animal models have been widely used, interspecies differences result in contradictions in clinical translation. Indeed, organ-on-chips have arisen as powerful tools to overcome these limitations. Organ-on-chips populated by human primary cells and/or stem cells can recapitulate in vivo organ level physiology and pathophysiology by recreating tissue and organ level functions in vitro. Cancer metastasis-on-chip models used to assess the efficacy of drug therapies are elaborated. In the short to medium term, more efforts are anticipated in engineering advanced microfluidic systems to develop organ-on-chip platforms for predictive translation of preclinical findings into clinical studies. © 2023 Published by the ISTES Organizationen_US
dc.description.sponsorshipTürkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK, (120N422)en_US
dc.identifier.endpage2059en_US
dc.identifier.isbn978-195209244-2
dc.identifier.issn2833-6747
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85184312453en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage2047en_US
dc.identifier.urihttps://hdl.handle.net/11454/103803
dc.identifier.volume9en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherThe International Society for Technology Education and Scienceen_US
dc.relation.ispartofProceedings of International Conference on Research in Education and Scienceen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectCancer modelsen_US
dc.subjectDrug discoveryen_US
dc.subjectEroom’s lawen_US
dc.subjectMicrofluidicsen_US
dc.subjectOrgan-on-chipen_US
dc.titleHas Humanizing the Drug Discovery and Development Process with Organ-On-Chips Contributed to Breaking Eroom’s Law?en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu